Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
TTLC 2019
IASLC 2019 Targeted Therapies of Lung Cancer Meeting
Access to all slides from presentations that occur during the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, CA
Presentation Date(s):- Feb 20 - 23, 2019
- Total Presentations: 232
-
+
01 - Opening Dinner and Keynote Lecture
- Type: General Session
- Track:
- Presentations: 6
- Slides Available
- Coordinates: 2/20/2019, 20:00 - 21:15, Starlight Ballroom
-
+
Opening Remarks (Slides Available)
19:00 - 19:05 | Author(s): Giorgio Scagliotti
- Abstract
No abstract available for this presentation
-
+
Introduction
19:05 - 19:10 | Author(s): Paul A. Bunn Jr.
- Abstract
No abstract available for this presentation
-
+
Dedication to Dr. Ki Hong (Slides Available)
19:10 - 19:15 | Author(s): Roy Herbst
- Abstract
No abstract available for this presentation
-
+
Dedication to Dr. Adi Gazdar (Slides Available)
19:15 - 19:20 | Author(s): John D. Minna
- Abstract
No abstract available for this presentation
-
+
Dedication to Dr. Adi Gazdar
19:15 - 19:20 | Author(s): Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
-
+
Identifying and Targeting Lung Cancer Vulnerabilities (Slides Available)
19:20 - 20:00 | Author(s): John D. Minna
- Abstract
No abstract available for this presentation
-
+
02 - Welcome to the IASLC 2019 Targeted Therapies of Lung Cancer Meeting
- Type: General Session
- Track:
- Presentations: 1
- Coordinates: 2/21/2019, 08:45 - 08:50, Starlight Ballroom
-
+
Welcome
07:45 - 07:50 | Author(s): Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
-
+
03 - Immune Checkpoint Inhibition Long Term Results and Biomarkers
- Type: General Session
- Track:
- Presentations: 11
- Slides Available
- Moderators:Ronan Kelly
- Coordinates: 2/21/2019, 08:50 - 10:05, Starlight Ballroom
-
+
Long Term Results with Single Agents (Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab) (Slides Available)
07:50 - 08:00 | Author(s): Roy Herbst
- Abstract
No abstract available for this presentation
-
+
Long Term Results With I/Os Above and Chemo (Slides Available)
08:00 - 08:10 | Author(s): Corey Langer
- Abstract
No abstract available for this presentation
-
+
Regeneron and Others (Slides Available)
08:10 - 08:15 | Author(s): Jacob Sands
- Abstract
No abstract available for this presentation
-
+
Sensitivity/Resistance to I/Os (Slides Available)
08:15 - 08:20 | Author(s): Katerina Politi
- Abstract
No abstract available for this presentation
-
+
Optimal Duration of Therapy (Slides Available)
08:20 - 08:25 | Author(s): David Spigel
- Abstract
No abstract available for this presentation
-
+
PDL1 (Slides Available)
08:25 - 08:30 | Author(s): Fred R. Hirsch
- Abstract
No abstract available for this presentation
-
+
Multiplex (Slides Available)
08:30 - 08:35 | Author(s): Kurt Schalper
- Abstract
No abstract available for this presentation
-
+
Circulating Immune Cells (Slides Available)
08:35 - 08:40 | Author(s): David P. Carbone
- Abstract
No abstract available for this presentation
-
+
ctDNA (Slides Available)
08:40 - 08:45 | Author(s): Max Diehn
- Abstract
No abstract available for this presentation
-
+
TMB Blood (Slides Available)
08:45 - 08:50 | Author(s): David R. Gandara
- Abstract
No abstract available for this presentation
-
+
TMB Tissue (Slides Available)
08:50 - 08:55 | Author(s): Naiyer Rizvi
- Abstract
No abstract available for this presentation
-
+
04 - TRK, ROS1 and ALK
- Type: General Session
- Track:
- Presentations: 11
- Slides Available
- Moderators:George Blumenschein
- Coordinates: 2/21/2019, 10:05 - 11:10, Starlight Ballroom
-
+
Entrectinib (TRK, ROS1) (Slides Available)
09:05 - 09:10 | Author(s): Robert Doebele
- Abstract
No abstract available for this presentation
-
+
Larotrectinib (Loxo101) (TRK) (Slides Available)
09:10 - 09:15 | Author(s): Anna Farago
- Abstract
No abstract available for this presentation
-
+
TPX005 (TRK, ROS1) (Slides Available)
09:15 - 09:20 | Author(s): Ignatius Ou
- Abstract
No abstract available for this presentation
-
+
Loxo 195 (TRK) (Slides Available)
09:20 - 09:25 | Author(s): Alexander Drilon
- Abstract
No abstract available for this presentation
-
+
Crizotinib (ALK, ROS1) (Slides Available)
09:25 - 09:30 | Author(s): Jessica Lin
- Abstract
No abstract available for this presentation
-
+
Alectinib (ALK) (Slides Available)
09:30 - 09:35 | Author(s): Shirish Gadgeel
- Abstract
No abstract available for this presentation
-
+
Brigatinib First Line (ALK) (Slides Available)
09:35 - 09:40 | Author(s): Ross Camidge
- Abstract
No abstract available for this presentation
-
+
Ensartinib (ALK) (Slides Available)
09:40 - 09:45 | Author(s): Leora Horn
- Abstract
No abstract available for this presentation
-
+
Lorlatinib (ALK, ROS1) (Slides Available)
09:45 - 09:50 | Author(s): Alice Shaw
- Abstract
No abstract available for this presentation
-
+
Brigatinib Following 2nd Generation ALK TKI (Slides Available)
09:50 - 09:55 | Author(s): Thomas Stinchcombe
- Abstract
No abstract available for this presentation
-
+
Where Do We Go From Here? (Slides Available)
09:55 - 10:05 | Author(s): Christine Lovly
- Abstract
No abstract available for this presentation
-
+
05 - Small Cell Lung Cancer
- Type: General Session
- Track:
- Presentations: 20
- Slides Available
- Moderators:Jeffrey Clarke
- Coordinates: 2/21/2019, 11:25 - 13:15, Starlight Ballroom
-
+
Lurbinectedin +/- Adriamycin (Slides Available)
10:25 - 10:30 | Author(s): William Petty
- Abstract
No abstract available for this presentation
-
+
INCB059872 (Slides Available)
10:30 - 10:35 | Author(s): Young Chae
- Abstract
No abstract available for this presentation
-
+
Pax 5 (BSAP) (Slides Available)
10:35 - 10:40 | Author(s): Ravi Salgia
- Abstract
No abstract available for this presentation
-
+
G1T28 (CDK, 4/6) (Slides Available)
10:40 - 10:45 | Author(s): John D. Heymach
- Abstract
No abstract available for this presentation
-
+
RRx001 (Radiosensitizer) (Slides Available)
10:45 - 10:50 | Author(s): Daniel Morgensztern
- Abstract
No abstract available for this presentation
-
+
PARP Inhibitors (Slides Available)
10:50 - 10:55 | Author(s): Ben Drapkin
- Abstract
No abstract available for this presentation
-
+
Navitoclax/Vistusertib (Slides Available)
10:55 - 11:00 | Author(s): Christine Hann
- Abstract
No abstract available for this presentation
-
+
EDO-S101 Tinostmustine (Alkylating Deacetylase) (Slides Available)
11:00 - 11:05 | Author(s): Jonathan Lehman
- Abstract
No abstract available for this presentation
-
+
Irinotecan + Dinutuxumab GD20 (Slides Available)
11:05 - 11:10 | Author(s): Taofeek Owonikoko
- Abstract
No abstract available for this presentation
-
+
Nanoirinotecan, Onivyde (Slides Available)
11:10 - 11:15 | Author(s): Anna Farago
- Abstract
No abstract available for this presentation
-
+
Tazemetostat (EZH2) (Slides Available)
11:15 - 11:20 | Author(s): Vamsidhar Velcheti
- Abstract
No abstract available for this presentation
-
+
IO + CCRT in LD-SCLC (Slides Available)
11:20 - 11:25 | Author(s): Kristin Higgins
- Abstract
No abstract available for this presentation
-
+
Atezoliziumab in ES-SCLC (Slides Available)
11:25 - 11:30 | Author(s): Stephen Liu
- Abstract
No abstract available for this presentation
-
+
Durvalumab + Olaparib (Slides Available)
11:30 - 11:35 | Author(s): Carl Gay
- Abstract
No abstract available for this presentation
-
+
Durva in LS and ES SCLC (Slides Available)
11:35 - 11:40 | Author(s): Roy Decker
- Abstract
No abstract available for this presentation
-
+
Nivolumab +/- Ipilimumab (Slides Available)
11:40 - 11:45 | Author(s): Neal Ready
- Abstract
No abstract available for this presentation
-
+
Pembrolizumab in ES-SCLC (Slides Available)
11:45 - 11:50 | Author(s): Patrick Ott
- Abstract
No abstract available for this presentation
-
+
ECOG Nivo + Chemo (Slides Available)
11:50 - 11:55 | Author(s): Ticiana Leal
- Abstract
No abstract available for this presentation
-
+
AMG757 (DLL-3) (Slides Available)
11:55 - 12:00 | Author(s): Taofeek Owonikoko
- Abstract
No abstract available for this presentation
-
+
Science (Slides Available)
12:00 - 12:10 | Author(s): Ravi Salgia
- Abstract
No abstract available for this presentation
-
+
06 - Debate #1 Patients with Stage 4 NSCLC TPS=20, PS2 Should Receive Chemo+IO
- Type: General Session
- Track:
- Presentations: 2
- Slides Available
- Moderators:Primo Lara
- Coordinates: 2/21/2019, 14:15 - 14:30, Starlight Ballroom
-
+
No - Chemo Alone or IO Alone (Slides Available)
13:15 - 13:30 | Author(s): Lawrence Einhorn
- Abstract
No abstract available for this presentation
-
+
Yes - Chemo + IO (Slides Available)
13:15 - 13:30 | Author(s): Bruce Johnson
- Abstract
No abstract available for this presentation
-
+
07 - EGFR/AXL
- Type: General Session
- Track:
- Presentations: 18
- Slides Available
- Moderators:Jack Lee
- Coordinates: 2/21/2019, 14:30 - 16:10, Starlight Ballroom
-
+
Dacomitinib (Slides Available)
13:30 - 13:35 | Author(s): Keunchil Park
- Abstract
No abstract available for this presentation
-
+
AC001 (EGFR) (Slides Available)
13:35 - 13:40 | Author(s): Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
Zn-e4 (EGFR)
13:40 - 13:45 | Author(s): Karen Reckamp
- Abstract
No abstract available for this presentation
-
+
EGF 816 (EGFR) (Slides Available)
13:45 - 13:50 | Author(s): Gregory Riely
- Abstract
No abstract available for this presentation
-
+
Osimertinib + Dasatinib (Slides Available)
13:50 - 13:55 | Author(s): Stephen Liu
- Abstract
No abstract available for this presentation
-
+
Osimertinib + Sapanisertib
13:55 - 14:00 | Author(s): Penelope Bradbury
- Abstract
No abstract available for this presentation
-
+
EGFR TKI + mAB (Slides Available)
14:00 - 14:05 | Author(s): Jonathan Riess
- Abstract
No abstract available for this presentation
-
+
Osimertinib + Navitoclax (Slides Available)
14:05 - 14:10 | Author(s): Eric Haura
- Abstract
No abstract available for this presentation
-
+
Osimertinib + Seleumetinib (Slides Available)
14:10 - 14:15 | Author(s): Mark Kris
- Abstract
No abstract available for this presentation
-
+
Osimertinib + Repotrectinib (Slides Available)
14:15 - 14:20 | Author(s): Ignatius Ou
- Abstract
No abstract available for this presentation
-
+
Osimertinib + CD73 Ab (Slides Available)
14:20 - 14:25 | Author(s): Sarah Goldberg
- Abstract
No abstract available for this presentation
-
+
AZD4635 + Oleclumab (Slides Available)
14:25 - 14:30 | Author(s): Benjamin Levy
- Abstract
No abstract available for this presentation
-
+
EGFR TKI + Bev (Slides Available)
14:30 - 14:35 | Author(s): Helena Yu
- Abstract
No abstract available for this presentation
-
+
Gefitinib + INC 280 (Slides Available)
14:35 - 14:40 | Author(s): Anne Chiang
- Abstract
No abstract available for this presentation
-
+
JNJ-6118637 (Bispecific EGFR/MET ab) (Slides Available)
14:40 - 14:45 | Author(s): Rachel Sanborn
- Abstract
No abstract available for this presentation
-
+
BGB324 (AXL) (Slides Available)
14:45 - 14:50 | Author(s): David Gerber
- Abstract
No abstract available for this presentation
-
+
Chemo + Bev + Atezolizumab (Slides Available)
14:50 - 14:55 | Author(s): Mark Socinski
- Abstract
No abstract available for this presentation
-
+
Where Do We Go Next? (Slides Available)
14:55 - 15:05 | Author(s): Katerina Politi
- Abstract
No abstract available for this presentation
-
+
08 - KRAS/BRAF
- Type: General Session
- Track:
- Presentations: 14
- Slides Available
- Moderators:Deborah Doroshow
- Coordinates: 2/21/2019, 16:40 - 18:05, Starlight Ballroom
-
+
MRTX849 (KRAS, G12 C)
15:40 - 15:45 | Author(s): Pasi Janne
- Abstract
No abstract available for this presentation
-
+
Binimetinib (MEK 1,2) (Slides Available)
15:45 - 15:50 | Author(s): Natasha Leighl
- Abstract
No abstract available for this presentation
-
+
ROS126766 (BRAF, MEK 1,2) (Slides Available)
15:50 - 15:55 | Author(s): Jose Pacheco
- Abstract
No abstract available for this presentation
-
+
LXH254 +/- LTT (Pan-RAF) (Slides Available)
15:55 - 16:00 | Author(s): Ibiayi Dagogo-Jack
- Abstract
No abstract available for this presentation
-
+
Cobimetinib + Atezolizumab (Slides Available)
16:00 - 16:05 | Author(s): Chad Pecot
- Abstract
No abstract available for this presentation
-
+
TAK580 (Non v600e) (Pan-RAF) (Slides Available)
16:05 - 16:10 | Author(s): Amber Johnson
- Abstract
No abstract available for this presentation
-
+
MEK162 + Erlotinib (MEK 1,2) (Slides Available)
16:10 - 16:15 | Author(s): Eric Haura
- Abstract
No abstract available for this presentation
-
+
Regorafinib + MTX (Multi-TKI) (Slides Available)
16:15 - 16:20 | Author(s): Sukhmani Padda
- Abstract
No abstract available for this presentation
-
+
SHP-2 Inhibitor RMC4630 (Slides Available)
16:20 - 16:25 | Author(s): Caroline McCoach
- Abstract
No abstract available for this presentation
-
+
LDOS001 (L-DOS47) (Urease Conjugation to AFAIKL2ab) (Slides Available)
16:25 - 16:30 | Author(s): Chandra Belani
- Abstract
No abstract available for this presentation
-
+
LY3214966 (ERK 1) (Slides Available)
16:30 - 16:35 | Author(s): Alex Adjei
- Abstract
No abstract available for this presentation
-
+
Palbociclib + PD0325901 (CDK 4,6 + MEK) (Slides Available)
16:35 - 16:40 | Author(s): Jared Weiss
- Abstract
No abstract available for this presentation
-
+
BVD523 (ERK 1,2) (Slides Available)
16:40 - 16:45 | Author(s): Bob Li
- Abstract
No abstract available for this presentation
-
+
Science Where Are We Going? (Slides Available)
16:45 - 16:55 | Author(s): Gregory Riely
- Abstract
No abstract available for this presentation
-
+
09 - Antibody Drug Conjugate
- Type: General Session
- Track:
- Presentations: 9
- Slides Available
- Moderators:David Ettinger
- Coordinates: 2/21/2019, 18:15 - 19:15, Starlight Ballroom
-
+
PF06647020 (PTK7) (Slides Available)
17:15 - 17:20 | Author(s): Jyoti Patel
- Abstract
No abstract available for this presentation
-
+
ABV 399 (MET) (Slides Available)
17:20 - 17:25 | Author(s): Jyoti Patel
- Abstract
No abstract available for this presentation
-
+
HuMax ACL ADC CAB (Slides Available)
17:25 - 17:30 | Author(s): Rathi Pillai
- Abstract
No abstract available for this presentation
-
+
Immu132 Sacituzumab (Trop2) (Slides Available)
17:30 - 17:35 | Author(s): Ross Camidge
- Abstract
No abstract available for this presentation
-
+
XMT 1536 (NaPi2b) (Slides Available)
17:35 - 17:40 | Author(s): Melissa Johnson
- Abstract
No abstract available for this presentation
-
+
CX2009 (Anti CD166) (Slides Available)
17:40 - 17:45 | Author(s): Gregory Riely
- Abstract
No abstract available for this presentation
-
+
Rovalpituzumab Theranostics (DLL3) (Slides Available)
17:45 - 17:50 | Author(s): J.T. Poirier
- Abstract
No abstract available for this presentation
-
+
AMG119 (DLL-3)
17:50 - 17:55 | Author(s): Lauren Byers
- Abstract
No abstract available for this presentation
-
+
Science (Slides Available)
17:55 - 18:05 | Author(s): Gregory Riely
- Abstract
No abstract available for this presentation
-
+
10 - Evening Fellows Session
- Type: General Session
- Track:
- Presentations: 8
- Moderators:Leora Horn
- Coordinates: 2/21/2019, 20:00 - 22:00, Starlight Ballroom
-
+
Patient Advocate
19:00 - 21:00 | Author(s): Janet Freeman-Daily
- Abstract
No abstract available for this presentation
-
+
Leadership - Division Director
19:00 - 21:00 | Author(s): Roy Herbst
- Abstract
No abstract available for this presentation
-
+
Community
19:00 - 21:00 | Author(s): Edward Kim
- Abstract
No abstract available for this presentation
-
+
Industry
19:00 - 21:00 | Author(s): Lee Krug
- Abstract
No abstract available for this presentation
-
+
Academic CE
19:00 - 21:00 | Author(s): Scott Lippman
- Abstract
No abstract available for this presentation
-
+
Government
19:00 - 21:00 | Author(s): Shakun Malik
- Abstract
No abstract available for this presentation
-
+
Academics PS
19:00 - 21:00 | Author(s): Katerina Politi
- Abstract
No abstract available for this presentation
-
+
Hybrid
19:00 - 21:00 | Author(s): David Spigel
- Abstract
No abstract available for this presentation
